ABL DiagnosticsXPAR:ABLD +0.80%50 Buyback Yield % is 1.87 as of Jul. 12, 2026, which is 19% above its 10-year median of 1.57. GuruFocus rates XPAR:ABLD with a GF Score™ of 50/100 and a GF Value™ of €7.77 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 274 Healthcare Providers & Services companies, ABL Diagnostics ranks better than 79.93% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for ABL Diagnostics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ABLD vs VEEV, BTSG, TEM: Buyback Yield % Comparison
For the Health Information Services subindustry, ABL Diagnostics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics Buyback Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Diagnostics (XPAR:ABLD) has a Buyback Yield % of 1.87 as of Jul. 12, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on ABL Diagnostics and its competitors. This is 19% above median its historical median of 1.57. According to the industry distribution chart, ABL Diagnostics ranks #55 out of 274 companies in the Healthcare Providers & Services industry, placing it in the top 20.1%.
Is ABL Diagnostics' Buyback Yield % too high?
ABL Diagnostics' current Buyback Yield % of 1.87 is 19% above median its 10-year median of 1.57. Based on the distribution chart, ABL Diagnostics ranks #55 out of 274 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, ABL Diagnostics has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' Buyback Yield % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #55 out of 274 companies for Buyback Yield %. This places ABL Diagnostics in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on ABL Diagnostics and its competitors. ABL Diagnostics's current Buyback Yield % is 1.87, which is 19% above median its own 10-year median of 1.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.77, compared to a current price of €2.52 — trading 67.6% below its estimated fair value. The current Buyback Yield % is 1.87, which is 19% above median its 10-year median of 1.57. ABL Diagnostics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current Buyback Yield % is 1.87 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.52 is trading 67.6% below its estimated GF Value™ of €7.77.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
Buyback Yield %: 1.87 (19% above median its 10-year median of 1.57)
GF Value™: €7.77 vs. price of €2.52 (67.6% below fair value)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
50GF Score
Get the complete analysis for XPAR:ABLD
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
